Moonwalk Biosciences Funding, Investors & Competitors

Moonwalk Biosciences has raised $127M across 2 funding rounds, most recently a $70M Series B in September 2026.

Last Moonwalk Biosciences funding round

$70M

Series B · Sep 2026

Cumulative funding Moonwalk Biosciences raised

$127M

across 2 funding rounds

Key investors in Moonwalk Biosciences

  • Khosla Ventures
  • ARCH Venture Partners
  • Alpha Wave Global
  • Future Ventures
  • YK Bioventures
  • GV
  • Gaorong Capital
  • Eli Lilly

Moonwalk Biosciences Overview

About Moonwalk Biosciences

Moonwalk Biosciences is a Boston-based genomic medicine startup engineering precision epigenetic therapeutics using AI-powered epigenome profiling. Founded in 2023 by Flagship Pioneering, it maps chromatin states across 100 cell types to identify disease modifiers in oncology and neurology. The platform combines single-cell sequencing with machine learning models trained on 1 million datasets. Moonwalk advances lead candidates into preclinical trials, partnering with Broad Institute for validation.


Founded

2022

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Moonwalk Biosciences Funding History

Moonwalk Biosciences has raised a total of $127M across 2 funding rounds.

Moonwalk Biosciences' first fundraising round was a $57M Series A in January 2024. The most recent completed round was a $70M Series B in September 2026.

Moonwalk Biosciences funding rounds

Moonwalk Biosciences funding rounds
DateStageInvestorsRaisedDeal Summary
Sep 2026Series BAlpha Wave Global (lead); YK Bioventures (lead); Future Ventures; Gaorong Capital; Khosla Ventures; Eli Lilly; ARCH Venture Partners$70MMoonwalk Biosciences closed a $70 million Series B financing on September 8, 2026, co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures, and existing investors ARCH Venture Partners, Khosla Ventures, and Future Ventures. The round is intended to advance the company’s lead obesity candidate, MW101, into first-in-human clinical studies in late 2027, expand its pipeline of adipose-selective RNAi medicines, and further develop its proprietary discovery platform. The financing comes as Moonwalk shifts its adipose-targeted RNAi program toward the clinic, building on prior support from a broad group of life sciences backers. Moonwalk is developing first-in-class adipose-targeted RNAi medicines for obesity and cardiometabolic diseases, with MW101 positioned as its lead program and additional tissue-targeted siRNA programs focused on distinct adipose biology. Moonwalk Biosciences is a South San Francisco- and San Diego-based biotechnology company focused on RNAi medicines and precision epigenetic medicine discovery. The company had previously raised $57 million in earlier financing and is using the new capital to support clinical translation of its obesity program and the broader adipose-targeted pipeline.
Jan 2024Series AAlpha Wave Global (lead); YK Bioventures; Future Ventures; GV; Khosla Ventures; ARCH Venture Partners$57MMoonwalk Biosciences is a genomic medicine company pioneering precision epigenetic medicines by targeting the epigenetic code, described as the software of the genome, to reprogram cells to a healthy state without altering the underlying DNA sequence. The company couples an epigenetic discovery platform with precise engineering tools, including EpiRead for mapping the epigenome at whole genome, single-cell resolution, and EpiWrite for multiplex epigenetic engineering, enabling novel discovery and therapeutic development for complex diseases. Co-founded by CEO Alex Aravanis, formerly of Illumina and Grail, and Feng Zhang of the Broad Institute, Moonwalk launched in April 2024 from South San Francisco and San Diego with a team of former Grail executives. On April 1, 2024, Moonwalk announced the completion of a combined $57 million seed and Series A financing round led by Alpha Wave Global (also referred to as Alpha Wave Ventures), with participation from ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures. The funding, totaling $57 million, will support advancement of its epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics toward the clinic. The company's differentiated approach includes the most advanced AI prediction of epigenetic targets and the broadest set of epigenetic engineering tools, positioning it to develop safer, more effective, and durable therapies across various indications. Investors highlighted the platform's potential to target disease root causes through epigenetic editing, with backing from firms experienced in gene editing and biotech innovation. Subsequent updates include presentations at ASGCT 2024 in April and ObesityWeek/Liver Meeting in late 2024, showcasing platform data.

Who has invested in Moonwalk Biosciences?

8 investors have backed Moonwalk Biosciences across its funding rounds, including Khosla Ventures, ARCH Venture Partners, Alpha Wave Global, Future Ventures, YK Bioventures and GV.

Lead investors include Alpha Wave Global and YK Bioventures.


Moonwalk Biosciences Investors

Investors in Moonwalk Biosciences by funding rounds participated
InvestorHQRoundsRoleFirst check
YK BioventuresUnited StatesUnited States2LeadJan 2024
Future VenturesUnited StatesSan Francisco, CA2ParticipantJan 2024
Khosla VenturesUnited StatesSan Francisco, CA2ParticipantJan 2024
Alpha Wave GlobalUnited StatesMiami, FL2LeadJan 2024
ARCH Venture PartnersUnited StatesChicago, IL2ParticipantJan 2024
GVUnited StatesSan Francisco, CA1ParticipantJan 2024

This data is available for Pro users. Sign up to see all 8 Moonwalk Biosciences investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Moonwalk Biosciences Competitors

Moonwalk Biosciences competitors include listed companies like Roche, Tempus AI and iFlytek, and private ones like SambaNova, Quantum Systems and Relativity Space.

Public and private companies comparable to Moonwalk Biosciences
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
RocheSwitzerlandSwitzerlandPublicly listed$77B$26B$351B4.9x
Tempus AIUnited StatesUnited StatesPublicly listed$1.3B($131M)$15B10.1x
iFlytekChinaChinaPublicly listed$4B$465M$14B3.4x
SambaNovaUnited StatesSan Francisco, CAPrivate$100M-$11B-
Quantum SystemsGermanyGilchingPrivate$330M-$8B24.2x
Relativity SpaceUnited StatesLos Angeles, CAPrivate--$4.2B-

Moonwalk Biosciences Public Comps

Moonwalk Biosciences is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, CrowdStrike, SAP and Amgen.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Eli Lilly$65B$28B16.5x13.1x38.7x27.0x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
AbbVie$61B$17B8.7x8.1x30.6x17.6x
Merck$65B$28B6.3x6.2x14.7x21.0x
Roche$77B$26B5.0x4.9x14.6x12.4x
Novartis$57B$22B5.5x5.5x14.2x13.3x
AstraZeneca$59B$19B4.8x4.5x14.6x12.7x
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x

This data is available for Pro users. Sign up to see all Moonwalk Biosciences competitors and their valuation data.

Start Free Trial

Common questions about Moonwalk Biosciences

When was Moonwalk Biosciences founded?Moonwalk Biosciences was founded in 2022.
Where is Moonwalk Biosciences headquartered?Moonwalk Biosciences is headquartered in San Francisco, CA, United States.
Is Moonwalk Biosciences publicly listed?No, Moonwalk Biosciences is a private, VC-backed company.
How much funding has Moonwalk Biosciences raised?Moonwalk Biosciences has raised $127M across 2 funding rounds.
What was Moonwalk Biosciences' last funding round?Moonwalk Biosciences' last funding round was a $70M Series B in September 2026, led by Alpha Wave Global and YK Bioventures.
Who are Moonwalk Biosciences' investors?Moonwalk Biosciences' investors include YK Bioventures, Future Ventures, Khosla Ventures, Alpha Wave Global, ARCH Venture Partners, GV, Gaorong Capital and Eli Lilly.
Which companies are comparable to Moonwalk Biosciences?Companies comparable to Moonwalk Biosciences include Roche, Tempus AI, iFlytek, SambaNova, Quantum Systems and Relativity Space.

See companies similar to Moonwalk Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial